The activation of Mylan’s Dutch poison pill anti-takeover defense Thursday ups the ante in the takeover war with the company’s spurned Israel-based suitor, Teva Pharmaceutical Industries, and could portend a court battle between the two generic drug giants.
Mylan’s defense is in the form of a foundation known as a “stichting,” which notified the company that it had exercised its call option to acquire 488.4 million Mylan preferred shares — essentially giving it control of half the company — and would use its voting power against Teva.
The separate foundation, which Mylan set up shortly after reincorporating in the Netherlands this year, said it took the action after concluding Mylan’s stakeholders were “at risk” because of the threat of a hostile takeover.
“Mylan follows a strategy of using financial leverage and retained profits to fuel further growth, whereas Teva has implemented a strategy of regular dividend payouts, a focus on cost control and product portfolio rationalization,” the Dutch foundation said in a statement.
Besides the “highly dissimilar business approach,” the foundation cited differences in culture and the potential for job losses and higher generic drug prices if the merger went through.
Some observers Thursday took issue with the foundation’s rationale, contending the two companies were more similar than different. One Wall Street analyst questioned the foundation’s independence.
Read More
“The stichting appears to equate stakeholder interest with defending [Mylan’s] management and the board,” Ronny Gal of Sanford Bernstein wrote in a note to clients. Among other things, he cited the “close parallel” between the foundation’s language and arguments used by Mylan in rejecting Teva’s roughly $40 billion bid in April.
Teva, meanwhile, which has built up a 4.6 percent stake in Mylan, quickly denounced the stichting for relying on “false assumptions” and signaled the company would fight back.
“We are well advised on Dutch law, including the ability of Mylan stockholders to challenge this action in court, and are prepared to take the necessary actions at the appropriate time,” Teva said in a statement.
Mylan, which maintains its operations base in Cecil after reincorporating in the Netherlands to cut its tax bill, has been working to block Teva’s $82-a-share offer and instead is pursuing a hostile bid for over-the-counter drug specialist Perrigo. Acquiring Perrigo, whose board so far has rejected Mylan, would make the company too big for Teva to swallow.
Mylan is planning a key shareholders meeting sometime in the third quarter to ask investors to approve its pursuit of Ireland-based Perrigo. If shareholders give Mylan the nod, Teva has said it will consider the vote a referendum on its offer and walk away.
Mylan’s foundation said Thursday it intended to use its shares at that meeting to “create a level playing field” and “restore stability” for Mylan’s management team.
“Otherwise, the stichting does not intend to use its voting powers to influence the outcome of the Mylan shareholder vote on the Perrigo transaction,” the foundation stated.
That likely means that the foundation is planning to cast the same percentage of shares that Teva controls in favor of the Perrigo transaction in order to “neutralize” Teva’s vote, Mr. Gal said.
In its announcement Thursday, the foundation said Mylan’s considerable manufacturing operations in India could be jeopardized in Teva’s hands.
“Teva has shown limited commitment to India or to developing markets,” it said.
“Teva has stated that it would not shut down Mylan’s facility in [Morgantown] West Virginia. The stichting believes that this makes it unlikely that the Mylan operations in India would remain unaffected.”
That prospect, the foundation said, “represents a serious risk that access to affordable generic products in developing markets will be significantly interrupted.”
In addition, the foundation said it believed that taking out Mylan — one of the top four players in the generic industry — would reduce competition and could raise generic drug prices in general.
The foundation also contended that part of the culture clash between Teva and Mylan involved “management compensation schemes.” It didn’t elaborate.
Teva, whose revenue of $20.3 billion in 2014 was almost three times that of Mylan’s $7.7 billion, pays its top executives considerably less than Mylan, according to proxy documents filed with the U.S. Securities and Exchange Commission.
Last year, Teva’s highest-paid executives, including CEO Erez Vigodman, collected $17 million in compensation, the documents show.
That compares with $73.5 million for Mylan’s top executives, including executive chairman Robert Coury, CEO Heather Bresch and president Rajiv Malik.
Mylan hasn’t yet announced a date for the Perrigo vote but is expected to do so soon. When it does, the public sparring between Mylan and Teva should heat up as both plead their cases to shareholders.
“Teva will likely pursue a challenge in the courts” to Mylan’s poison pill, Morningstar analyst Michael Waterhouse said in an email.
Such a challenge “continues to make any predictions about how this plays out highly uncertain.”
The chairman of Mylan's foundation is Pieter Bouw, the former CEO of Dutch airline KLM.
Mylan shares gave up $1.34, or 1.97 percent, Thursday to close at $66.56. Teva was unchanged at $62.51.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.